West Pharmaceutical Services stock reports 13.80 percent revenue growth

Published on 10/01/2026 at 00:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

West Pharmaceutical Services stock posted Q2 2026 revenue of USD 872.30 million, up 13.80 percent year over year. Fiscal 2026 EPS guidance stands at USD 8.85 to USD 9.05.

Reinraum-Fertigung von Vials, West Pharmaceutical, ISIN US9523901012 — West Pharmaceutical (ISIN US9523901012) stellt in sterilen Reinräumen Vials und Elastomer-Verschlüsse für Injektionssysteme her, Illustration mit AI erstellt.

West Pharmaceutical Services (ISIN US9553061055) delivered USD 872.30 million in revenue in Q2 2026, an increase of 13.80 percent from the year-earlier quarter. The results and fiscal outlook give WST a concrete earnings anchor as the next report approaches.

Revenue growth beats expectations

According to MarketBeat on September 27, 2026, West reported Q2 EPS of USD 2.37 against a USD 2.08 analyst consensus. The USD 0.29 difference was accompanied by revenue of USD 872.30 million versus a consensus estimate of USD 839.98 million.

The comparison matters because the quarter combined double-digit revenue growth with an earnings beat. West also guided for fiscal 2026 EPS of USD 8.85 to USD 9.05, giving investors a defined range for the full-year profit outlook.

Analyst target remains above stock

MarketBeat reported on September 25, 2026, that fourteen brokerages carried a consensus Moderate Buy rating and an average 12-month target of USD 382.00. Against the USD 370.76 NYSE price on September 30, 2026, that target stood 3.03 percent above the stock.

The analyst picture is not uniform. Yahoo Finance listed Morgan Stanley upgrading West to Overweight on September 22, 2026, while raising its target from USD 365.00 to USD 400.00. The higher target is a separate broker view from the broader USD 382.00 consensus.

Stock remains below yearly high

WST traded at USD 370.76 on the NYSE on September 30, 2026 at 4:02 p.m. EDT. Its USD 26.1 billion market capitalization and USD 223.83 to USD 386.00 52-week range place the price 3.95 percent below the yearly high.

West Pharmaceutical Services says it generated USD 3.07 billion in fiscal 2025 net sales, operates on the NYSE under WST and is included in the S&P 500. The company develops injectable containment and delivery solutions, linking its earnings profile to pharmaceutical packaging and drug delivery demand.

Yahoo Finance lists October 22, 2026 as the next earnings date for West Pharmaceutical Services. That report will test whether the Q2 revenue pace and the USD 8.85 to USD 9.05 fiscal 2026 EPS guidance remain on track.